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Abstract Pituitary adenomas account for ∼10% of intra-
cranial tumors, and they cause the compression of nearby
structures and the inappropriate expression of pituitary
hormones. Unlike functional pituitary adenomas, nonfunc-
tional (NF) pituitary adenomas account for ∼30% of
pituitary tumors, and are large enough to cause blindness;
because they do not cause any clinical hormone hyperse-
cretion, they are difficult to detect at an early stage; and
hypopituitarism results. No effective molecular biomarkers
or chemical therapy have been approved for the clinical
setting. Because an NF pituitary adenoma is highly
heterogeneous, differences in the proteins (the proteome)
can distinguish among those heterogeneity structures. The
components of a proteome dynamically change as an NF
adenoma progresses. Changes in protein expression and
protein modifications, individually or in combination,
might be biomarkers to predict the disease, monitor the
tumor progression, and develop an accurate molecular
classification for personalized patient treatment. The mo-
dalities of proteomic variation might also be useful in the
interventional prevention and personalized treatment of
patients to halt the occurrence and progression of NF
pituitary adenomas.
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CDKI cyclin-dependent kinase inhibitor
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ESI electrospray ionization
FSH follicle-stimulating hormone, or follitropin
GH growth hormone
IL1 interleukin 1
IPA Ingenuity Pathway Analysis
JNK c-Jun N-terminal kinase
LCM laser-capture microdissection
LH luteinizing hormone, or lutropin
MALDI matrix-assisted laser desorption/ionization
MAPK mitogen-activated protein kinase
MAPKK MAPK kinase
MAPKKK MAPKK kinase
Mr relative molecular mass
MS mass spectrometry
MS/MS tandem mass spectrometry
MW molecular weight
NF nonfunctional
Nrf2 nuclear factor E2-related factor-2
NTAC nitrotyrosine affinity column
pI isoelectric point
PKA cyclic AMP-dependent kinase
PMF peptide mass fingerprint
PRL prolactin
PTM post-translational modification
RKIP raf kinase inhibitory protein
RNS reactive nitrogen species
ROS reactive oxygen species
SELDI surface-enhanced laser desorption/ionization
TNF tumor necrosis factor
TOF time-of-flight
TSH thyrotropin-stimulating hormone, or
thyrotropin
Introduction
Pituitary adenomas are a common pathological change that
account for ∼10% of intracranial tumors [1]. They cause
significant morbidity through a compression of regional
structures and an inappropriate expression of pituitary
hormones that disturb the multiple hypothalamic-pituitary-
target organ axis systems. Pituitary adenomas are clinically
classified as functional (∼70%; such as acromegaly and
prolactinoma) and nonfunctional (∼30%). Unlike functional
pituitary adenomas, nonfunctional (NF) pituitary adenomas
are typically quite large, do not cause any clinical hormone
hypersecretion, and result in hypopituitarism or blindness
from regional compression. Moreover, an NF pituitary
adenoma is highly heterogeneous in the cell of origin [1].
Therefore, an early-stage diagnosis of NF pituitary adeno-
mas is difficult because there is no hormone hypersecretion
and there is no effective chemical therapy for NF pituitary
adenomas. Predictive diagnosis/prevention and early-stage
diagnosis/clinical therapy are the crucial aspects needed to
conquer a tumor because most of NF pituitary adenomas
remain as late-stage diagnosed and neurosurgically/radia-
tion treated. Modern proteomics methods provide insight
into the proteome, which is a dynamically changing
protein-network system that progresses with disease. Study
of the proteomic variations will result in new concepts and
models for the more-accurate prediction, prevention, and
personalized patient therapy for NF pituitary adenomas.
This review article addresses the contribution of tissue-
proteomic variations to the interventional prevention and
personalized patient treatment, and the contribution of
body-fluid proteomic variations to the predictive diagnosis
and the assessment of preventive and therapeutic responses.
Pathophysiological basis for the variation
of the proteome in an NF pituitary adenoma
Pituitary adenomas are monoclonal in the cell of origin
[2, 3], and might arise from any one of five pituitary
anterior cell types (Fig. 1) [4, 5]—including corticotrophs
[secrete adrenocorticotropic hormone (ACTH)], somato-
trophs [secrete growth hormone (GH)], lactotrophs [secrete
prolactin (PRL)], thyrotrophs [secrete thyrotropin-
stimulating hormone, or thyrotropin (TSH)], and gonado-
trophs [secrete follicle-stimulating hormone, or follitropin
(FSH) and luteinizing hormone, or lutropin (LH)]—to
produce an imbalance in hormone levels that will disturb
the multiple regulatory hypothalamic-anterior pituitary-
target organ axes. Each axis performs a range of important
physiologic functions in the human body (Fig. 1). Mixed-
tumors (co-secrete GH with PRL, TSH, or ACTH) might
also arise from single cells. ACTH oversecretion results in
Cushing’s disease, with features of hypercortisolism; GH
hypersecretion leads to acral overgrowth and metabolic
dysfunction associated with acromegaly; and PRL overse-
cretion leads to gonadal failure, secondary infertility, and
galactorrhea. More rarely, TSH hypersecretion leads to
hyperthyroxinemia and goiter, and hypersecreted GH (or
GH subunits) leads to gonadal dysfunction. In contrast,
tumors that arise from gonadotroph cells do not efficiently
secrete their gene products, and they are usually clinically
silent [4]. They are commonly referred to as NF pituitary
adenomas, which cannot be diagnosed early because no
hormone change is observed. However, NF pituitary
adenomas are highly heterogeneous in the cell of origin
(Table 1) [1]. Except for a gonadotroph-originated intact
LH/FSH adenoma (up to 79% of NF adnomas), immuno-
cytochemical staining of hormones also reveals that some
NF pituitary adenomas might arise from a silent cortico-
troph (ACTH-positive; 8%), silent somatotroph (GH-posi-
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tive; 3%), no hormone-expressed oncocytoma (6%), and
null cell (17%).
Those heterogeneous cells of origin of NF pituitary
adenomas produce differences in a proteome relative to the
control and among different NF pituitary adenoma patients,
and that difference in the proteome dynamically changes
with tumor progression. The proteomic difference among
different types of NF pituitary adenomas, and the dynamic
alteration with tumor progression, both contribute to the
prediction, interventional prevention, and personalized
patient treatment of NF pituitary adenoma patients.
Targeted organs of proteomic variation that contribute
to the prediction, prevention, and personalized
treatment of an NF pituitary adenoma
The pituitary is the most-protected organ in the body, and is
the master regulatory gland; several different hypothalamic-
pituitary-target organ axes exist. Any metabolic defect in
those regulatory systems has an associated pathology.
Based on the new concept of prediction, prevention, and
personalized patient treatment of an NF pituitary adenoma,
pituitary tissues, cerebrospinal fluid (CSF), and blood
plasma must be analyzed. Any tissue-proteome variation
directly reflects the pathophysiological changes of an NF
pituitary adenoma. Those tissue-proteome variations, and
the corresponding changes in the biological system, can be
developed into an accurate molecular classification, inter-
ventional prevention, and personalized patient treatment. In
Table 1 Classification of nonfunctional pituitary adenomas by cell of
origin





Null cell None 17
Oncocytoma None 6
Silent corticotroph ACTH 8
Silent somatotroph GH 3
Reproduced from Oyesiku [1], with permission from AACR,
copyright 2005.
Fig. 1 Scheme of the hypothalamic-anterior pituitary-target organ
axis systems and pituitary adenoma pathogenesis [4]. (+)=stimulatory
regulation; (−)=inhibitory regulation. Reproduced from Zhan and
Desiderio [5], with permission from Wiley-VCH, copyright 2005; and
modified from Melmed [4], with permission from Copyright Clearance
Center Inc. (Re: Journal of Clinical Investigation), copyright 2003
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addition, in an NF pituitary adenoma patient, some secreted
proteins and peptides will enter into the CSF and blood
circulation. Comparative proteomics can detect those
different components (proteins or peptides) in the patient’s
CSF and blood plasma. Those CSF and blood plasma
proteomic and peptidomic variations will lead to the
development of an accurate predictive diagnosis and the
measurement of interventional prevention and therapy
response based on accurate molecular data.
Pituitary tumor tissues are generally acquired with
neurosurgery from patients, whereas control tissues are
generally obtained via forensic anatomy from post-mortem
cardavers. Therefore, there is some uncontrollable bias
among pituitary adenoma tissues and “so-called” control
tissue proteome such as sex, age, race, and time of tissue
acquisition; and some biochemical changes might occur in
post-mortem tissue compared to surgical tissue. Also, an
NF pituitary adenoma is monoclonal in origin, and is
generally benign. An NF pituitary adenoma tissue contains
a relatively pure cell population, whereas control post-
mortem pituitary tissues contain different types of cells,
including at least corticotrophs, somatotrophs, lactotrophs,
thyrotrophs, and gonadotrophs, etc. When the tumor tissues
and post-mortem tissues are used to analyze the proteomic
variation, another bias is possible. The use of laser-capture
microdissection (LCM) to preferentially enrich a specific
tumor cell type from tumor tissues and the corresponding
normal cells from post-mortem tissues overcomes this bias.
Compared to a tissue proteome, those limitations do not
exist for the CSF and blood specimens. Also, CSF and
blood specimens are much more accessible from patients
and controls than the pituitary tissues.
Techniques to measure proteomic variation
Modern proteomics uses protein-separation techniques such
as gel and non-gel methods, protein-identification techni-
ques such as mass spectrometry (MS), multiple protein-
preparation techniques, and systems biology techniques to
quantitatively measure proteomic variation in tissue, CSF,
and blood plasma samples from patients and controls.
Gel methods include two-dimensional gel electrophore-
sis (2DGE) and 2D differential in-gel electrophoresis (2D
DIGE). 2DGE-based comparative proteomics is a classical,
reliable method to quantify accurately any proteomic
variation. Briefly, proteins are arrayed with 2DGE accord-
ing to their pI and Mr, and are stained. Each 2D gel spot-
volume reflects the abundance of the protein contained in
that spot. Each individual gel spot-volume is generally
normalized with the total spot-volumes of each gel image
[6, 7]. 2DGE images from tumors and controls are
compared with 2D gel-analysis software to obtain statisti-
cally significant differential 2D gel spot-volume between
tumors and controls. The amino acid sequence of a protein
in each 2D gel spot is obtained with MS, including peptide
mass fingerprint (PMF) (which determines the MW of each
tryptic peptide from that protein) and/or tandem mass
spectrometry (MS/MS) (which determines the amino acid
sequence of each tryptic peptide), and corresponding
protein database analysis [8].
2D DIGE is another gel method to quantify the
proteomic variation [9–11]. Generally, the tumor and
control samples are labeled with different fluorescent dyes
such as CyDye 3 and CyDye 5. The CyDye-labeled
samples are mixed equally (1:1), and the mixed sample is
separated with 2DGE according to pI and Mr. The proteins
are visualized, and the image is scanned with a CyDye 3
channel and CyDye 5 channel to form two fluorescent
images, which are processed with DeCyder DIGE analysis
software or Delta 2D software. Any color difference in a
gel spot defines and quantifies the protein content between
tumors and controls. The amino acid sequence of tryptic
peptides from each protein in each gel spot is determined
with MS/MS. 2D DIGE is more useful to analyze precious
LCM-enriched samples because 2D DIGE requires less
protein amount and fewer gel-analysis procedures relative
to the traditional 2DGE-based comparative proteomics.
Non-gel methods mainly include the analysis of trypsin-
digests from a complex mixture of proteins with multidimen-
sional chromatography coupled on-line with MS [12, 13].
That strategy generates tryptic peptides that are separated in
the first dimension with any one of several different
chromatographies, and with reversed-phase chromatography
in the second dimension. The separated peptides are
analyzed with MS/MS, and the amino acid sequences are
analyzed with a database analysis for protein identification.
The technique has been used to analyze some human tissue
proteomes [14]. For quantification of proteomic variation,
that technique must be coupled with stable-isotope labeling
prior to multidimensional-chromatography analysis [15].
The light and heavy isotope-labeled peptides were quanti-
fied with MS/MS to quantify and identify the protein
amount between tumor and control proteomes. A wide
variety of stable isotope-labeling techniques have been
developed; for example, cysteine-specific tagging such as
ICAT [16], lysine-specific tagging [17, 18], and amine-
specific tagging such as iTRAQ [19–21]. Moreover, some
software has been developed to quantitatively analyze the
stable isotope-labeled peptides; for example, XPRESS
software for ICAT-labeled peptides. Non-gel methods
effectively detect low-abundance proteins, extremely acid-
ic/basic proteins, and low/high-Mr proteins. Although the
gel methods are limited by the extremely acidic (pI<3.5 or
4)/basic (pI>7.5 or 8) proteins, extremely high-mass
(>150 kDa) or low-mass (<10 kDa) proteins, and hydro-
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phobic proteins [5], the non-gel techniques are complemen-
tary with the gel-based methods, and improve the proteomic
coverage of an NF pituitary adenoma proteome.
Systems biology techniques such as pathway analysis
help to elucidate each protein variation within a pathway
network system. The development of bioinformatics and
computation biology underpins systems biology develop-
ments. A wide-range of pathway analysis programs has
been developed such as Ingenuity Pathway Analysis (IPA)
(www.ingenuity.com) and MetaCore (www.genego.com/
metacore.php). Pathway analysis has been used to mine
significant pathway networks from pituitary adenoma tissue
comparative proteomic data and proteomic modification
data [22]. The recovery of the tumor-altered pathway
system to the normal pathway system would contribute
significantly to interventional prevention and effective
chemical therapy. Those proteomic variations include
variations in protein expression and post-translational
modifications (PTMs).
Tissue proteomic variations that contribute to accurate
molecular classification, interventional prevention,
and personalized patient treatment
A tissue proteome is a systematic and tightly regulated
protein-network system that dynamically changes during
pathophysiological processes. Multiple endogenous and
exogenous factors cause an alteration of certain elements
within a proteome relative to controls. Those altered
elements include protein differential expression (DEPs),
splicing isoforms (such as hormone isoforms), and protein
modifications (such as tyrosine nitration and phosphoryla-
tion), etc.
A total of 56 DEPs has been identified among NF
adenomas and controls with 2DGE comparative proteomics
strategies (Table 2) [1]. A large-scale comparative proteo-
mics study was performed on a set of human pituitary
samples [1, 5, 23]: controls (n=8) versus several different
cell-types of NF pituitary adenomas (NF-, n=3; LH+, n=3;
FSH+, n=3; FSH+/LH+, n=3) and hyperprolactinomas (n=
4). A total of 93 differential protein-spots (65 decreased
spot volumes, 28 increased) were found in NF pituitary
adenomas and prolactinomas. Seventy-two spots (50
decreased, 22 increased) that represented 56 DEP’s (34
down-regulated, 22 up-regulated) were characterized with
MS and database analysis. Functional roles are summarized
in Fig. 2. Results indicated that: (i) neuroendocrine-related
proteins, including somatotropin, secretagogin, and mu-
crystallin homolog, were down-regulated in NF pituitary
adenomas and the hyperprolactinoma; (ii) somatotropin
existed in at least 17 isoforms that were down-regulated in
NF adenomas and the hyperprolactinomas; (iii) prolactin
existed in six isoforms that were down-regulated in NF
adenomas, and no-change in the hyperprolactinomas; (iv)
immunologic regulation proteins and tumor-related antigen
(for example, immunoglobulin, tumor-rejection antigen 1)
were down-regulated in NF adenomas; (v) cell prolifera-
tion, differentiation, and apoptosis-related proteins were
down-regulated in the NF-adenomas and the hyperprolacti-
nomas; (vi) some cell-defense and stress-resistance proteins
(for example, phospholipid hydroperoxide glutathione
peroxidase, CD59 glycoprotein, and heat-shock 27 kDa
protein) were down-regulated in the NF pituitary adenomas;
(vii) some metabolic enzyme-related proteins (for example,
cytoplasmic isocitrate dehydrogenase [NADP], tryptophan
5-hydroxylase 2, matrix metalloproteinase-9, aldose reduc-
tase, lactoylglutathione lyase, acyl-CoA-binding protein,
etc.) were up-regulated in the NF pituitary adenomas; and
(viii) for cell-signal proteins, some were down-regulated
and some were up-regulated in NF adenomas; those cell
signals are involved in the complex biological roles in the
cell growth, proliferation, differentiation, apoptosis, and
death cycles.
The heterogeneity of hormone expression is an important
characteristic in an NF pituitary adenoma. Protein isoforms
result from protein PTMs, splicing, etc. A comparative
proteomics study of NF adenomas demonstrated that two
hormones (GH and PRL) had multiple isoforms [1, 23].
Twenty-four 2D gel spots that contained GH were found in
control pituitary tissues [24] (Fig. 3). Those hGHs in the 24
2D gel spots were classified into four types of hGH-splicing
isoforms, 1–4. The expression proportion of those four
isoforms were isoform 1 (87.5 %) > isoform 2 (8.1 %) >
isoform 3 (3.3 %) > isoform 4 (1.1 %) (Fig. 4); and a
significant statistical difference was found among those
isoforms. Not all of isoforms related to NF pituitary
adenomas [1]. Somatotropin was significantly down-
regulated at the protein and the mRNA levels in the NF
pituitary adenoma [1] and in prolactinomas [23]; that
finding is consistent with their monoclonal origin [2, 3]—
an NF adenoma originated from gonadotrophs, and a
prolactinoma from lactotrophs; the GH receptor gene was
unchanged. Those data showed that GH hyposecretion in
an NF-adenoma results from the hypo-expression of the GH
gene. However, the more important finding is that the
multiple GH isoforms (17 spots contain somatotropin) were
detected [1, 23]; those data cannot be interpreted from
transcriptomics data. The down-regulated ratio of the
different GH isoforms was different in each cell-type of
NF pituitary adenoma relative to the controls. Those data
suggested that the proportion of the different GH isoforms
changed in each cell-type NF adenoma compared to
controls. Other researchers showed that the proportion of
a circulating GH isoform significantly changed in pituitary
adenomas and other pituitary diseases [25, 26]. The
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Table 2 Differentially expressed proteins identified in human nonfunctional pituitary adenoma tissues with 2DGE-based comparative proteomics
ID Molecules Fold-change Description Location Function
P49753 ACOT2 5.8 acyl-CoA thioesterase 2 C enzyme
P15121 AKR1B1 14.6 aldo-keto reductase family 1B1 C enzyme
P02647 APOA1 −3.2 apolipoprotein A-I EC transporter
P06576 ATP5B 5.0 ATP synthase, H+transporting, mitochondrial
F1 complex, beta polypeptide
C transporter
P47756 CAPZB 6.5 capping protein (actin filament) muscle
Z-line, beta
C other
CAPZB CAPZB 6.5 capping protein (actin filament) muscle
Z-line, beta
C other
P13987 CD59 −9.5 CD59 molecule, complement regulatory
protein
PM other
P12110 COL6A2 −14.7 collagen, type VI, alpha 2 EC other
P14854 COX6B1 9.3 cytochrome c oxidase subunit Vib
polypeptide 1 (ubiquitous)
C enzyme
Q14894 CRYM −35.3 crystallin, mu C enzyme
CSN1S1 CSN1S1 (includes
EG:1446)
−17.8 casein alpha s1 EC other
P07108 DBI 4.3 acyl-Coenzyme A binding protein C other
Q9UHL4 DPP7 −9.3 dipeptidyl-peptidase 7 C peptidase
Q14259 ERH 5.0 enhancer of rudimentary homolog N other
P30040 ERP29 4.6 endoplasmic reticulum protein 29 C transporter
P00742 F10 −83.0 coagulation factor X EC peptidase
P06241 FYN 3.9 FYN oncogene related to SRC, FGR,YES PM kinase
P31150 GDI1 9.4 GDP dissociation inhibitor 1 C other
P01241 GH1 −180.6 growth hormone 1 EC cytokine
P01241 GH1 −13.3 growth hormone 1 EC cytokine
P01241 GH1 −13.3 growth hormone 1 EC cytokine
P01241 GH1 −20.2 growth hormone 1 EC cytokine
P01241 GH1 −14.1 growth hormone 1 EC cytokine
P01241 GH1 −128.3 growth hormone 1 EC cytokine
P01241 GH1 −14.8 growth hormone 1 EC cytokine
P01241 GH1 −48.1 growth hormone 1 EC cytokine
P01241 GH1 −17.3 growth hormone 1 EC cytokine
P01241 GH1 −16.9 growth hormone 1 EC cytokine
P01241 GH1 −88.8 growth hormone 1 EC cytokine
P01241 GH1 −27.8 growth hormone 1 EC cytokine
P01241 GH1 −51.2 growth hormone 1 EC cytokine
P01241 GH1 −32.1 growth hormone 1 EC cytokine
P01241 GH1 −478.6 growth hormone 1 EC cytokine
P01241 GH1 −13.4 growth hormone 1 EC cytokine
P01241 GH1 −161.0 growth hormone 1 EC cytokine
P01241 GH1 −37.0 growth hormone 1 EC cytokine
P01242 GH2 −14.1 growth hormone 2 EC other
Q04760 GLO1 10.2 glyoxalase I C enzyme
Q04760 GLO1 8.3 glyoxalase I C enzyme
P09471 GNAO1 9.5 G protein, alpha activating activity
polypeptide O
PM enzyme
P29777 GNAO1 9.5 G protein, alpha activating activity
polypeptide O
PM enzyme
P36969 GPX4 −26.1 glutathione peroxidase 4 C enzyme
P28161 GSTM2 4.2 glutathione S-transferase M2 (muscle) C enzyme
HBB HBB (includes EG:3043) −3.1 hemoglobin, beta C transporter
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Table 2 (continued)
ID Molecules Fold-change Description Location Function
HBB HBB (includes
EG:3043)
−99.4 hemoglobin, beta C transporter
P02081 HBD −3.1 hemoglobin, delta C transporter
P14625 HSP90B1 −11.0 HSP90 beta (Grp94), member 1 C other
P04792 HSPB1 −5.1 heat shock 27 kDa protein 1 C other
Q9UJY1 HSPB8 −3.7 heat shock 22 kDa protein 8 C kinase
O75874 IDH1 8.7 isocitrate dehydrogenase 1 (NADP+), soluble C enzyme
P24592 IGFBP6 −20.9 insulin-like growth factor binding protein 6 EC other
IGLC1 IGLC1 −32.1 immunoglobulin lambda constant 1 C other
IGLC3 IGLC3 −32.1 immunoglobulin lambda constant 3 NA other
P08779 KRT16 −28.8 keratin 16 (focal non-epidermolytic
palmoplantar keratoderma)
C other
Q86U44 METTL3 −8.3 methyltransferase like 3 N enzyme
Q99542 MMP19 3.1 matrix metallopeptidase 19 EC peptidase
P12524 MYCL1 −17.8 v-myc myelocytomatosis viral oncogene
homolog 1, lung carcinoma derived (avian)
N transcription
regulator
O00217 NDUFS8 5.2 NADH-coenzyme Q reductase C enzyme
P20774 OGN −38.0 osteoglycin EC growth factor
Q08752 PPID 5.1 peptidylprolyl isomerase D (cyclophilin D) C enzyme
Q00007 PPP2R2A −8.2 protein phosphatase 2 (formerly 2A),
regulatory subunit B, alpha isoform
C phosphatase
P01236 PRL −99.9 prolactin EC cytokine
P01236 PRL −9.7 prolactin EC cytokine
P01236 PRL −26.2 prolactin EC cytokine
P01236 PRL −20.1 prolactin EC cytokine
P01236 PRL −36.7 prolactin EC cytokine
P01236 PRL −33.6 prolactin EC cytokine
O76038 SCGN −6.6 secretagogin C other
Q9UI15 TAGLN3 5.6 transgelin 3 NA other
P21980 TGM2 −17.1 transglutaminase 2 C enzyme
Q8IWU9 TPH2 10.6 tryptophan hydroxylase 2 NA enzyme
O14530 TXNDC9 −11.4 thioredoxin domain containing 9 NA other





theta polypeptide (14-3-3 protein tau)
C other
Q14584 ZNF266 7.3 zinc finger protein 266 N other
IL15-S21AA P40933-2 −2.7 Splice isoform IL15-S21AA of interleukin-15
P01620 −32.1 Ig kappa chain V-III region SIE
IGLC2 P01842 −32.1 Ig lambda chain C regions
P01621 −32.1 Ig Kappa chain V-III region NG9
P04433 −32.1 Ig kappa chain V-III region VG
HBB2 P18988 −3.1 Hemoglobin beta-2 chain (PANLE)
gi 1066765 −176.7 Hemoglobin beta unit variant
HBB2 P18988 −99.4 Hemoglobin beta-2 chain (PANLE)
P01935 −99.4 Hemoglobin alpha-3 chain (PANTR)
P01968 −20.2 Hemoglobin alpha-2 chain (BOSMU)
HBB2 P18988 −20.2 Hemoglobin beta-2 chain (PANLE)
C, cytoplasm; EC, extracellular space; PM, plasma membrane; N, Nucleus; NA, unknown. Modified from Zhan and Desiderio [1, 22], with
permission from AACR, copyright 2005; and with permission from BioMed Central open access journal, copyright remains with the authors.
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proportional change of the different GH isoforms might
have an important value in the clinical evaluation of NF
adenomas. Recently, studies found that GH isoforms were
derived from a variety of splicing variants and PTMs,
including phosphorylation [24]. The phosphorylation of
endogenous GH in the human pituitary [27] provided new
insights into the mechanisms of GH that participate in the
neuroendocine signal pathways.
Prolactin is another important pituitary hormone. Six
prolactin isoforms were detected with proteomics [1, 23].
Similar to GH, each prolactin isoform was down-regulated
in each cell-type NF adenoma, with a different down-
regulated ratio relative to controls. There was no significant


































Fig. 2 Functional categories of the 56 DEPs. A Down-regulated
proteins in pituitary adenoma (34): I. Neuro-endocrine and hormones;
II. Cytokine and cellular signal-related proteins; III. Cellular defense
and stress resistance; IV. mRNA splicing, transport, or translation-
related enzymes; V. DNA-binding proteins; VI. Metabolic enzymes;
VII. Immunologic regulation proteins and tumor-related antigen; VIII.
Transport proteins; IX. Cell proliferation, differentiation, and
apoptosis-related proteins; X. Others. B Up-regulated proteins in
pituitary adenomas (22): I. Metabolic enzyme-related proteins; II.
Energy metabolism; III. Cellular signal proteins; IV. Cell cycle, cell
growth and proliferation proteins; V. Cellular defense response; VI.
Protein folding-related protein; and VII. Others. Reproduced from
Zhan and Desiderio [5], with permission from Wiley-VCH, copyright
2005
Fig. 3 MS-characterized GH isoforms in a 2-DE map of human
pituitary. IEF was performed with an IPG dry strip (18 cm, pH 3–10
nonlinear). SDS-PAGE was performed with a polyacrylamide (12%)
resolving gel. The protein in each labeled spot was MS-characterized.
Reproduced from Zhan and Desiderio [24], with permission from
Wiley-VCH, copyright 2005
Fig. 4 Expression proportion of the four splicing isoforms of GH in
human pituitary glands. Reproduced from Zhan and Desiderio [24],
with permission from Wiley-VCH, copyright 2005
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mRNA levels in the prolactinoma relative to controls; that
finding is consistent with a prolactinoma’s monoclonal
origin. However, the proportion of those six prolactin
isoforms changed in NF adenomas and prolactinomas
compared to controls.
Other researchers showed that glycosylation is an
important prolactin modification [28] that produces differ-
ent isoforms; glycosylation of human prolactin might
down-regulate its hormone bioactivity and promote its
metabolic clearance [29]. Other studies showed that the
main variant of prolactin was the non-glycosylated form of
PRL in human prolactinomas [30]; that finding is consistent
with the result that some prolactin isoforms were down-
regulated in prolactinomas compared to controls [23]. Thus,
it has been speculated that the prolactin isoform in those
down-regulated spots was possibly a glycosylated prolactin.
Therefore, further detailed study of the different isoforms
and PTMs of GH and prolactin could lead to new insights
into the clinical importance of pituitary hormones in the
formation of an NF adenoma. The ratio of the change of
each isoform in a human pituitary tissue has value for
clinical research.
Except for protein-expression variation and splicing
isoforms, protein PTMs are an important source of
proteome variation that is associated with different patho-
physiological processes. Also, the degree and the sites of
the PTMs could dynamically change with pathophysiolog-
ical processes.
Oxidative/nitrative stresses are involved in a variety of
tumorigenesis mechanisms. DEP analyses [1] demonstrated
that many reactive-oxygen species (ROS)-related proteins
were changed in human pituitary adenomas, including
heat shock protein, cytochrome P450, GST, and phospho-
lipid hydroperoxide glutathione peroxidase (Table 2). An
important oxidative stress-related modification—tyrosine
nitration—was studied in an NF adenoma [31] and a post-
mortem control [32, 33]. 2DGE-based nitrotyrosine West-
ern blot and MS/MS identified eight nitroproteins from a
pituitary control (Table 3) [32, 33]. Those control nitro-
proteins are involved in the transforming growth factor beta
1 (TFGB1) and actin cellular skeleton signaling networks
(Fig. 5a), which function in gene expression, cellular
development, and connective-tissue development [22]. The
nitroproteins in that network include SNAP91, FCAR, actin,
PRKG2, STC1, PAQR3, and PSMA2. Nitrotyrosine affinity
column (NTAC)-based MS/MS identified nine nitroproteins,
and three non-nitrated proteins that interact with nitro-
proteins, from a NF adenoma [31] (Table 3). Those NF
adenoma nitroproteins and their complexes are involved in
the tumor necrosis factor (TNF) and interleukin 1 (IL1)
signaling networks (Fig. 5b), which function in cancer, cell
cycle, and reproductive-system disease [22]. The nitro-
proteins in that network include ARHGAP5, PRKAR1B,
PSMA2, IL1F6, and RHPN2. The non-nitrated proteins that
interact with nitroproteins include IRAK2, GRIP2, and
ubiquitin. Three nitroprotein-protein complexes were iden-
tified: the nitrated proteasome-ubiquitin complex, the
nitrated beta-subunit of PKA complex, and the nitrated
IL1F6-IL1 receptor-IL1 receptor-associated kinase-like 2
(IL1F6-IL1R-IRAK2) complex. Two pathway networks
(Fig. 5 a and b) include a same beta-estradiol signal
pathway, which indicates that hormone metabolism involves
the control pituitary and pituitary adenoma. This result is
consistent with the fact that NO participates in pituitary
hormone metabolism in normal physiology, and that a tumor
interferes with hormone metabolism. Based on the docu-
mented functions of those identified proteins, each nitro-
protein and nitroprotein-protein complex was rationalized
into the corresponding functional system (Fig. 6) [31]. The
nitrated CENTβ1 and the nitrated PKAR1β are involved in
the cAMP-dependent protein-kinase signal pathway. The
nitrated RHOGAP5 and the nitrated rhophilin 2 are involved
in the GTPase signal pathway. IRAK-2 in the IL1-R
complex and the nitrated IL1-F6 are involved in the
cytokine system. The nitrated ZFP432 is involved in
transcription regulatory systems. The nitrated S1P lyase 1
participates in sphingolipid metabolism to regulate cell
proliferation, survival, and cell death [34] as well as the
immune system [35, 36]. The nitrated LIRA4 might be
involved in the immune system. The nitrated proteasome-
ubiquitin complex is an important enzymatic complex that is
involved in the intracellular nonlysosomal proteolytic
pathway [37, 38]. These data demonstrate that those
nitroproteins and nitroprotein-protein complexes might
participate in several different and very important functional
pathways in human pituitary tumor cells.
Four pathway-network systems, including mitochondrial
dysfunction, oxidative stress, cell-cycle dysregulation, and
MAPK-signal abnormality for the NF adenoma, were
generated from those DEP and nitroprotein data [22].
Those four pathway-network systems have been described
in detail [22]. (i) Mitochondrial dysfunctions underlie a
broad spectrum of human diseases [39, 40] that includes
cancer [41, 42], neurodegenerative diseases [43], cardio-
vascular diseases [44], diabetes mellitus [45], and inflam-
matory diseases [46, 47]. Notable differences in the
structure and function of mitochondria appear between
cancer and normal cells [41, 42]. Mitochondrial dysfunc-
tions have been proposed as a cause of cancer [48], are a
biomarker for the early detection of cancer, and are a
therapeutic target for cancer. Figure 7 shows the canonical
pathway of mitochondrial dysfunctions [22]. Mitochondrial
dysfunction could be confirmed with a mitochondrial
morphological change and the increased number of mito-
chondria in a human pituitary tumor [49–52]. Mitochondria
are emerging as biomarker targets for the early detection of,
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Table 3 Nitroproteins and non-nitrated proteins identified in a pituitary adenoma [31], and control tissue [32, 33]
Pituitary adenoma Pituitary control
Protein name nY site Protein name nY site
Nitrated protein: Nitrated protein:
Rho-GTPase-activating 5 [Q13017] (ARHGAP5) Y550 Synaptosomal-associated protein (SNAP91) Y237
Leukocyte immunoglobulin-like
receptor A4 [P59901]
Y404 Ig alpha Fc receptor [P24071] (FCAR) Y223
Zinc finger protein 432 [O94892] Y41 Actin [P03996] (ACTA2, ACTG2, ACTC1) Y296
PKA beta regulatory subunit
[P31321] (PRKAR1B)
Y20 PKG 2 [Q13237] (PRKG2) Y354
Sphingosine-1-phosphate lyase 1 [O95470] Y356, Y366 Mitochondrial co-chaperone protein
HscB [Q8IWL3]
Y128
Centaurin beta 1 [Q15027] Y485 Stanniocalcin 1[P52823] (STC1) Y159
Proteasome subunit alpha type 2
[P25787] (PSMA2)
Y228 Proteasome subunit alpha type 2 (PSMA2) Y228
Interleukin 1 family member 6
[Q9UHA7] (IL1F6)
Y96 Progestin and adipoQ receptor family
member III [Q6TCH7] (PAQR3)
Y33
Rhophilin 2 [Q8IUC4] (RHPN2) Y258
Nitroprotein-interacting protein
Interleukin-1 receptor-associated kinase-like 2
(IRAK-2) [O43187] (IRAK2)
Glutamate receptor interacting protein 2
[Q9C0E4] (GRIP2)
Ubiquitin [P62988] (UBB or UBC)
Modified from Zhan and Desiderio [31–33], with permission from Elsevier, copyright 2004, 2006, and 2007.
A. B.
AdenomaControl
Enzyme; Peptidase; Kinase; Phosphatase; Cytokine or regulator; Others.Note:
Fig. 5 Significant signaling pathway networks that are involved in
human pituitary adenoma nitroproteomic data. Network A derives
from control nitroproteomic data, and functions in gene expression,
cellular development, and connective-tissue development and func-
tion. A gray node denotes an identified nitroprotein. Network B
derives from adenoma nitroproteomic data, and functions in cancer,
cell cycle, and reproductive-system disease. A gray node denotes an
identified nitroprotein, or a protein that interacts with nitroproteins. An
orange solid-edge denotes a direct relationship between two nodes
(molecules: proteins; genes). An orange nonsolid-edge denotes an
indirect relationship between two nodes (molecules: proteins; genes).
The various shapes of nodes denote the different functions. A curved
line means intracellular translocation; a curved arrow means extracel-
lular translocation. Reproduced from Zhan and Desiderio [22], with
permission from BioMed Central open access journal; copyright
remains with the authors
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Fig. 6 Experimental data-based model of nitroproteins and their functions in human nonfunctional pituitary adenomas. NO2−, nitroprotein.








Fig. 7 Mitochondrial dysfunctional pathway network. Red label=
upregulated, green label=downregulated. The various shapes of nodes
denote the different functions. A duplicated shape means this node
contains multiple components. An arrow denotes the pathway
direction. A line with a small circle denotes a biological result.
Reproduced from Zhan and Desiderio [22], with permission from
BioMed Central open access journal; copyright remains with the
authors
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and for novel therapeutic targets in, cancer [48, 53–56]. (ii)
Oxidative stress occurs when the balance is disturbed
between an upload of free-radical/reactive oxygen/nitrogen
species (ROS/RNS) from in vivo formation and from in
vitro environmental carcinogens, and the capability of
endogenous antioxidant defense mechanisms to remove
those reactive species [57, 58]. Many studies have indicated
that ROS and RNS are involved in pituitary adenoma
pathology [59–61]. A nitroproteomics study [31] discov-
ered nine tyrosine-nitrated proteins in human pituitary
adenoma tissues, and each tyrosine nitration site is located
within an important protein domain to alter protein
functions. However, with the formation of ROS and RNS,
the in vivo antioxidative mechanism is also initiated against
ROS/RNS [62]. Pivotal to the antioxidant response is the
transcription factor Nrf2 (nuclear factor-E2-related factor-
2). DEP and nitroproteomic data clearly reveal that the
Nrf2-mediated oxidative-stress response pathway system
(Fig. 8) is involved in an NF pituitary adenoma. Any
decrease in the capability of this antioxidant protective
system could increase the susceptibility to oxidative stress,
tumor inflammation, carcinogen toxicity, and tumorigene-
sis. Therefore, the oxidative stress-antioxidative stress-
response system could be the novel target to develop
effective therapeutic agents that could be used for human
pituitary adenomas [63, 64]. (iii) Cell-cycle dysregulation is
involved in an NF pituitary adenoma. The basic biological
characteristics of tumor cells are the unrestricted prolifer-
ation and growth that are controlled by the dysregulated
cell-cycle. The cell cycle is regulated by a cyclically
operating biochemical system that includes cyclins,
cyclin-dependent kinases (CDK), and their inhibitors
(CDKI) [65]. Studies have demonstrated that the ectopic
expression of cyclin D and the overexpresion of Cyclins A,
B, and E occur in an NF pituitary adenoma to regulate
different phases of the cell cycle, and to accelerate the
progression of the cell-cycle [65]. The details on cell-cycle
dysregulation in a human pituitary adenoma have been
reviewed [66–69]. The pathway analysis of NF pituitary
adenoma nitroproteomic data and DEP data clearly revealed
the cell-cycle G2/M DNA damage checkpoint-regulation
pathway (Fig. 9) in NF adenomas. The important cell-cycle
regulator 14-3-3 protein was down-regulated (44-fold) in
NF adenomas compared to controls (Table 2). Moreover,
nitroproteomic data demonstrate that a nitrated proteasome
could interfere with the functions of the ubiquitin-
proteasome system in the regulation of the cell cycle. The
proteasome inhibitors can induce apoptosis in GH-and
prolactin-secreting rat pituitary tumor cells through a
blocking of the cell cycle at the G2/M transition [70]. (iv)
MAPK-signaling abnormality operates in an NF pituitary
adenoma. MAPK-signaling pathways link the extracelluar
signal stimuli to functional cellular processes such as
growth, proliferation, migration, and apoptosis. The basic
MAPK pathway is stimulus (mitogens, growth factors,
cytokines, stress, etc.) ➔ G-protein (Ras, Rac, Cdc42, Rho)
➔ MAPKKK (Raf, Tpl2, MEKK, MLK, TAK, ASK, TAO)
➔ MAPKK (MEK) ➔ MAPK (ERK, JNK, P38) to
generate responses (proliferation, differentiation, apoptosis,
and migration). ERKs (extracellular signal-regulated
kinases), JNKs (c-Jun N-terminal kinases), and p38-
MAPKs are the three main subfamilies of MAPKs. The
details of MAPK-signaling pathways in cancer have been
reviewed [71–73]. The MAPK pathways are emerging as
potential therapeutic targets for cancer [74, 75], and the
development of inhibitors of MAPK pathways has a
growing importance in cancer therapy. The pathway
analyses of NF adenoma proteomic data clearly demon-
strate that MAPK-signaling pathways are involved in
pituitary tumorigenesis. DEP proteomic data show that
Ras, ERK, JNK, p38-MAPK, Akt, TNF, TGFb1, MAPK,
and NFkB are the key nodes in their pathway networks, and
that ERK/MAPK signaling (Fig. 10) is the significant
canonical pathway in adenomas. The nitroproteomic data
of NF adenomas show that TNF and IL1B are the key nodes
in their pathway networks, and that p38-MAPK signaling
(Fig. 11) is the significant canonical pathway that partic-
ipates in an oxidative-stress response in an adenoma.
Moreover, the PKA type I beta regulatory subunit is nitrated
in human pituitary adenomas (Fig. 6; Table 3), and tyrosine
nitration occurs within the dimerization region [31]; those
nitrations could interfere with dimerization and affect PKA
activity to suppress Raf activity. Recent studies demonstrate
that an overexpression of B-Raf mRNA and protein is a
feature of NF adenomas; that overactivity highlights an
overactivity of the Ras-B-Raf-MAP kinase pathway to
promote pituitary tumorigenesis [76], and that the low levels
of Raf kinase inhibitory protein (RKIP) in a GH-pituitary
adenoma correlate with a poor clinical response to somato-
statin analog therapy because RKIP can bind to and inhibit
Raf1 kinase to attenuate MAPK signaling [77].
Those NF pituitary adenoma-related tissue proteome
data demonstrate clearly that crucial elements in the
proteome-network system occur as variations in the NF
adenoma pathology, offer systematic concept to treat NF
pituitary adenoma patients, and could improve patient
healthcare. From a prospective viewpoint, those altered
crucial elements in the NF pituitary adenoma tissue
proteomic network system could have three main uses: (i)
Fig. 8 NRF2-mediated oxidative-stress response pathway. Red label=
upregulated, green label=downregulated. The various shapes of nodes
denote the different functions. A duplicated shape means this node
contains multiple components. An arrow denotes the pathway
direction. A line with a small circle denotes a biological result.
Reproduced from Zhan and Desiderio [22], with permission from
BioMed Central open access journal; copyright remains with the
authors
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The accurate molecular classification of NF pituitary
adenoma, which is necessary for an NF pituitary adenoma,
because an NF pituitary adenoma is highly heterogeneous
(Table 1). (ii) Interventional prevention of NF pituitary
adenomas, which will be an important strategy to eliminate
NF adenoma in the pre-clinical stage for population
healthcare. Tissue quantitative and comparative proteomics
can identify the crucial protein elements unique to an NF
pituitary adenoma in the proteome-network systems. From
those crucial protein elements, an accurate pharmacological
intervention could be developed. The high-risk population
that will be identified with body fluid (serum; CSF)
biomarkers will benefit from those drugs to recover their
proteome to the normal status, and to eliminate NF pituitary
adenomas at the pre-clinical stage, which will significantly
benefit the pituitary adenoma populations and reduce social
economical load. (iii) Personalized proteomic therapy for an
NF pituitary adenoma patient. The proteome differs among
different type of NF pituitary adenomas, and dynamically
alters with disease pathophysiological processes. With the
development of proteomic techniques, computation biology,
and system biology, the complete proteomic databases
unique to each cell-type of NF pituitary adenomas, and
different pathophysiological stages, will be accurately
established. The individualized unique proteomic elements
will be determined for each patient. Toward those personal-
ized proteomic elements, one could apply protein-
engineering techniques to correct for those altered proteomic
elements to the normal status in the proteome-network
system in order to realize personalized patient treatment
and to halt disease progression, which will provide a highly
efficacious therapy, and will reduce the patient costs
compared to traditional therapy strategy.
Body-fluid proteomic and peptidomic variations
that potentially will contribute to the predictive
diagnosis and the measurement of interventional
prevention and therapy response
CSF and blood serum are two important body fluids that are
used for pituitary adenoma studies. CSF around the brain
and spinal cord contains peptides (several hundred) and
proteins (about 1000) that are important for brain physiol-
ogy [78], and is an excellent source of peptides and proteins
that are secreted during brain-tumor development, and also
potentially relevant to brain pathology. Serum is another
important biological fluid that is an excellent source of
peptides and proteins that are metabolized during pituitary-
tumor pathological processes. Serum proteomes and pepti-
Cell cycle G2/M DNA damage checkpoint regulation
Enzyme; Kinase; Phosphatase; Cytokine or regulator; Others.Note:
Fig. 9 Pathway component for
cell cycle G2/M DNA damage
checkpoint regulation. The vari-
ous shapes of nodes denote the
different functions. A duplicated
shape means this node contains
multiple components. An arrow
denotes the pathway direction.
A line with a small circle
denotes a biological result.
Reproduced from Zhan and
Desiderio [22], with permission
from BioMed Central open ac-
cess journal; copyright remains
with the authors
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domes contain resident hemostatic proteins, immunoglobu-
lins, cytokines, hormones, secreted proteins, exogenous
proteins, peptides; infection indictors; and also tissue-
leakage proteins such as those released from damaged or
dying cells [79]. Therefore, blood serum contains accurate
molecular information on the physiological state of all
tissues/organs in the body, and changes with disease status.
Monitoring the changes in the peptide and protein compo-
sition of an NF pituitary adenoma patient’s CSF and serum
can be used as a sensitive and accurate molecular indicator
of tumor pathology. Also, CSF and blood specimens are
easily accessible from patients and controls, with minimal
invasion. Moreover, CSF and blood specimens that are
from different pathological stages can be obtained at
different time-points. Therefore, CSF and blood serum/
plasma are excellent targets to develop early-stage diag-
nostic markers, and to develop the assessment indices to
measure the interventional prevention and therapy response
for NF pituitary adenomas.
We state here an important paradigm shift: in the future,
multiple-parameter pattern-diagnostic markers and assess-
ment indices of prevention and therapy response will
replace the single-parameter biomarker for the prediction,











Fig. 10 ERK/MAPK signaling
pathway. Red label=upregu-
lated, green label=downregu-
lated. The various shapes of
nodes denote the different func-
tions. A duplicated shape means
this node contains multiple
components. An arrow denotes
the pathway direction. A line
with a small circle denotes a
biological result. Reproduced
from Zhan and Desiderio [22],
with permission from BioMed
Central open access journal;
copyright remains with the
authors
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adenomas. The reason for that paradigm shift is that a
traditional single-molecule biomarker is based on an
unrealistic assumption that an increase in the amount of a
single compound can unambiguously specify a disease.
However, the reality is that NF pituitary adenomas are
characterized by a heterogeneity among patients; pituitary
adenomas are initiated by numerous factors, and cause a
range of different molecular changes. For example, a
significant elevation of blood GH and prolactin has been
useful to predict and diagnose acromegaly and prolatinoma,
respectively. However, a large number of acromegaly and
prolactinoma patients are still detected at an advanced
stage. For the NF pituitary adenomas, no blood hormone
levels are elevated, almost all NF pituitary adenomas are
diagnosed at a late stage, and no molecular indices measure
the therapy response and prognosis. Multiple-parameter
biomarkers from serum or CSF will resolve these problems
in the prediction, prevention, and personalized treatment
assessment of an NF pituitary adenoma.
Several promising multiparameter strategies from serum
or CSF proteomes and peptidomes might meet those
requirements, and include protein/peptide pattern diagnos-
tics, protein microarrays, and an antibody microarray.
Serum/CSF protein/peptide pattern diagnostics This diag-
nostic is an MS-based technique; namely, use the pattern
variation of MS peaks to diagnose disease. The concept
behind pattern diagnostics is that the CSF/blood serum
proteome/peptidome reflects the pituitary tumor tissue and
organ pathology that cause patterns of body-fluid protein/
peptide changes that have diagnostic potential without even
knowing the identities of the individual proteins/peptides
[79]. MS can be used to detect that pattern of peaks that
correspond to the intact proteins or peptides, and that peak
pattern can be used to discriminate among different stages
of tumor from controls. The prediction diagnosis and
prognostic monitoring becomes the comparison of the
pattern or “signature” of the proteins or peptides. A
p38 MAPK signaling
Enzyme Kinase Phosphatase Cytokine or regulator OthersNote:
Fig. 11 The p38 MAPK signal-
ing pathway. A gray label
denotes an identified protein.
The various shapes of nodes
denote the different functions. A
duplicated shape means this
node contains multiple compo-
nents. An arrow denotes the
pathway direction. A line with a
small circle denotes a biological
result. Reproduced from Zhan
and Desiderio [22], with per-
mission from BioMed Central
open access journal; copyright
remains with the authors
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serum-protein pattern has been used to predict and assess
laryngeal squamous cell carcinoma [80] and ovarian cancer
[81]. Surface-enhanced laser desorption/ionization time-of-
flight mass spectrometry (SELDI-TOF-MS) has been used
in this protein-pattern recognition [80, 81]. Serum or CSF
samples from tumor and controls were individually applied
to a SELDI chip. The retained proteins on the chip were
subsequently ionized (MALDI) and detected with TOF-
MS. Corresponding bioinformatics software was used to
compare the MS spectra and to determine the differential
pattern of peaks to discriminate tumors from controls. This
approach has been used to identify a “signature” protein
pattern within a “training set” of SELDI-TOF MS spectra
that contained 50 female ovarian cancer sera and 50 female
control sera [81]. The identified “signature” protein pattern
was used to identify ovarian cancer in individuals within a
new independent “validation set” that contained 50 female
ovarian cancer sera and 66 female control sera, with a
positive predictive value of 94%, sensitivity of 100%, and
specificity of 95% [81].
However, even though SELDI-TOF MS was the most
commonly used instrument for this protein-pattern recog-
nition, some problems remain to be resolved for the SELDI
method: (i) What is the total amount (moles) of ionizable
groups (positive, negative) due to Lys, Arg, Asp, Glu, etc.
in the biological samples? (ii) What is the total number
(moles) of ionizable groups on the SELDI sample probe
surface? (iii) What is the ratio of (i)/(ii) in the SELDI
experiments? (iv) Does the sample exceed, and/or chemi-
cally modify, the chromatography capability of the SELDI
probe surface? (v) SELDI does not allow a direct
identification of the discriminatory proteins and suffers
from low reproducibility, sensitivity, and accuracy [82–86].
To overcome some of those problems, Dekker et al. used
MALDI-TOF-MS to replace SELDI-TOF-MS; the body-
fluid samples were first digested with trypsin, and the
tryptic peptide mixtures were analyzed with MALDI-TOF-
MS to obtain the tryptic-peptide profile for each sample to
diagnose leptomeningeal metastases in breast cancer
patients with an accuracy of 77%, a sensitivity of 79%,
and a specificity of 76% [82, 87].
Thempst et al. developed a signature serum-peptide
pattern to predict metastatic thyroid carcinomas [88, 89].
The plasma peptides were isolated with magnetic beads,
and were analyzed with a MALDI-MS scan to obtain MS
spectra. The pattern of peaks that corresponded to the
serum peptides were identified in a “training setting”;
subsequently, the serum-peptide pattern was used to
discriminate the tumors from controls in an independent
“validating setting”. This serum-peptidome pattern was
used to distinguish metastatic thyroid carcinomas from
cancer-free controls with 95% sensitivity and 95% speci-
ficity (binomial confidence intervals, 75.1–99.9%) [89].
CSF protein pattern and peptide patterns are also under
development to diagnose CNS system disease with a
similar strategy [78, 82]. Amino acid sequence data are
needed in those studies.
The serum/CSF protein/peptide pattern-recognition ap-
proach is emerging as a promising method for cancer
prediction and diagnosis, and also offers the promise to
measure the interventional prevention and therapeutic
response. However, one should clearly realize that the
standardized common serum/CSF-sample handing proce-
dure [90] and the large-scale samples analyzed [79] are
essential, and that this pattern-recognition method would
have more potential in combination with other genetic
factor analysis [79], and with amino acid sequence data.
Protein/antibody microarray This technique is derived
from DNA-microarray technologies without the use of
MS to detect any proteomic variation. It is another
promising approach for prediction diagnosis and for the
measurement of interventional prevention and therapeutic
response. Briefly, a protein microarray immobilizes
thousands of protein-detecting features on a microchip.
This microchip is incubated with a biological sample to
detect any proteomic pattern variation in the disease relative
to controls. The common protein array refers to an antibody
array that hosts different antibodies such as monoclonal,
polyclonal, and antibody fragments to detect their respec-
tive antigens from human blood samples. An example is the
cytokine-antibody array to detect inflammation-related
disease [91]. Another type of protein microarray is to
directly immobilize multiple functional proteins onto a
microchip to detect protein-protein, protein-ligand, enzyme-
substance, protein-DNA interactions, and PTMs, which is
also called a “functional protein array” [92–94]. An
example is the whole-proteome array from yeast that
contains 5,000 purified proteins immobilized onto a glass
microscope slide [95]. With the prospective to identify the
serum/CSF protein/peptide patterns of NF pituitary adeno-
ma, those signature protein/peptides or their antibodies
could be immobilized onto a microchip for the predictive
diagnosis and the measurement of preventive and thera-
peutic response for NF pituitary adenoma patients.
Conclusions
The traditional assessment of the level of one serum-
hormone is difficult to detect clinical NF pituitary adeno-
mas; furthermore, no effective chemical therapy exists to
treat an NF pituitary adenoma. An NF pituitary adenoma
contains highly heterogeneous cell types that are the
distinguishing pathophysiological basis that causes the
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proteomic variation. In combination with multiple endog-
enous and exogenous factors, that proteome variation is the
basis for personalized patient treatment. A more accurate
multiple-parameter global systematic strategy will replace
the limited single-factor strategy in the prediction, preven-
tion, and personalized treatment of NF pituitary adenomas.
The global-proteomic strategy offers the promise for the
multiple-parameter assessment for the predictive diagnosis,
measurement of preventive and therapeutic response, and
personalized patient treatment. The diagram of the use of
proteomic variations to predict, prevent, and personalize
treatment of NF adenomas is shown (Fig. 12). A tissue
proteomic-variation study would lead to the accurate
molecular classification of an NF adenoma, and the
modality of proteomic variation for interventional preven-
tion and halting the tumor progression. The serum/CSF
proteomic/peptidomic variation would lead to serum/CSF
protein/peptide pattern diagnostics, and the protein/anti-
body microarray for the predictive diagnosis and measure-
ment of interventional prevention and personalized
therapeutic response. Briefly, a tumor-tissue proteomic-
variation study would lead to an accurate molecular
classification that will contribute to identification of
personalized patients. Modalities of the altered tissue-
proteome of a personalized patient will realize the person-
alized treatment of NF pituitary adenomas. This therapeutic
response will be assessed with body-fluid (serum and/or
CSF) proteomic/peptidomic variations to determine wheth-
er tumor progression is inhibited or halted. The high-risk
population that might develop an NF pituitary adenoma will
be determined with a predictive diagnosis strategy—body-
fluid (serum and/or CSF) proteomic/peptidomic variations.
Modalities of the altered tissue-proteome of the high-risk
population will realize the interventional prevention. This
preventive response will be assessed with body-fluid
(serum and/or CSF) proteomic/peptidomic variations to
determine the preventive effects and whether tumor
occurrence is halted. In summary, any proteomic variation
is tightly associated with NF pituitary adenoma progres-
sion. The detection and modalities of proteomic variation
will serve an effective role in the prediction, prevention,
and personalized treatment of NF pituitary adenoma
patients.
Proteomic variations offer numerous opportunities to
predict, prevent, and provide a personalized treatment
(PPPM) for NF pituitary adenomas. Currently, whole
tissue-proteome variations (protein expression; hormone
isoforms; modifications) are studied in NF pituitary
adenomas, and the significant signal pathway networks
associated with NF pituitary adenomas are mined from those
whole tissue-proteome variation data. Four important
pathway-network systems, including mitochondrial dysfunc-
tion, oxidative stress, cell-cycle dysregulation, and MAPK-
signal abnormality, for the NF adenoma are identified. The
follow-up studies of those tissue proteome data would
contribute to the accurate molecular classification for the
diagnosis of personalized patients and their personalized
treatment. However, some problems remain to be resolved
towards that PPPM goal: (i) the complete tissue-proteomic
databases unique to single-cell type pituitary adenomas, and
Pituitary adenoma proteome
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Fig. 12 Diagram of the use of
proteomic variations to predict,
prevent, and personalize treat-
ment for NF pituitary adenomas
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different pathophysiological stages, must be accurately
established towards the development of individualized
unique proteomic elements for each patient. Recently, laser-
captured single-cell type pituitary prolactinoma cells have
been used for proteomics analysis [96]. (ii) The complete
body-fluid (serum; CSF) proteomic/peptidomic databases
unique to single-cell type pituitary adenomas, and different
pathophysiological stages, must be accurately established.
For body-fluid proteomic/peptidomic databases, a large-scale
of normal population is needed towards the development of
the predictive diagnostic pattern. (iii) The novel techniques
such as protein-engineering techniques must be developed to
correct for those altered personalized proteomic elements to
the normal status in the proteome-network system towards
an interventional prevention in the high-risk population and
for the personalized treatment of NF pituitary adenomas. (iv)
The comprehensive computation model system needs to be
developed to integrate all proteomic data, personal data,
clinical data, and other genetic data towards the facile and
accurate predictive diagnosis of the high-risk population and
an accurate assessment of preventive and therapeutic
responses.
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